L Gifre1, J Vidal2, J L Carrasco3, A Muxi4, E Portell2, A Monegal5, N Guañabens5,6, P Peris5,6. 1. Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clinic of Barcelona, Villarroel 170, Barcelona, 08036, Spain. lgifre@clinic.ub.es. 2. Guttmann Neurorehabilitation Institute, Universitat Autònoma de Barcelona, Badalona, Spain. 3. Public Health Department, University of Barcelona, Barcelona, Spain. 4. Nuclear Medicine Department, Hospital Clinic of Barcelona, Barcelona, Spain. 5. Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clinic of Barcelona, Villarroel 170, Barcelona, 08036, Spain. 6. CIBERehd, Madrid, Spain.
Abstract
UNLABELLED: Osteoporosis is a frequent complication related to spinal cord injury (SCI), and data on osteoporosis treatment after SCI is scarce. Treatment with denosumab increases lumbar and femoral BMD and decreases bone turnover markers in individuals with recent SCI. This drug may be a promising therapeutic option in SCI-related osteoporosis. INTRODUCTION: Osteoporosis development is a frequent complication related to SCI, especially at the sublesional level. Nevertheless, data on osteoporosis treatment after SCI is scarce, particularly short term after injury, when the highest bone loss is produced. The aim of this study was to analyze the efficacy of denosumab in the treatment of SCI-related osteoporosis. METHODS: Fourteen individuals aged 39 ± 15 years with osteoporosis secondary to recent SCI (mean injury duration 15 ± 4 months) were treated with denosumab for 12 months. Bone turnover markers (BTMs) (PINP, bone ALP, sCTx), 25-hydroxyvitamin D (25OHD) levels and bone mineral density (BMD) at the lumbar spine (LS), total hip (TH), and femoral neck (FN) were assessed at baseline and at 12 months. All participants received calcium and vitamin D supplementation. RESULTS: At 12 months, SCI denosumab-treated participants showed a significant increase in BMD at TH (+2.4 ± 3.6 %, p = 0.042), FN (+3 ± 3.6 %, p = 0.006), and LS (+7.8 ± 3.7 %, p < 0.001) compared to baseline values. Denosumab treatment was associated with significant decreases in BTMs (bone ALP -42 %, p < 0.001; PINP -58 %, p < 0.001, sCTx -57 %, p = 0.002) at 12 months. BMD evolution was not related to BTM changes or 25OHD serum levels. No skeletal fractures or serious adverse events were observed during follow-up. CONCLUSIONS: Treatment with denosumab increases lumbar and femoral BMD and decreases bone turnover markers in individuals with recent SCI. This drug may be a promising therapeutic option in SCI-related osteoporosis.
UNLABELLED: Osteoporosis is a frequent complication related to spinal cord injury (SCI), and data on osteoporosis treatment after SCI is scarce. Treatment with denosumab increases lumbar and femoral BMD and decreases bone turnover markers in individuals with recent SCI. This drug may be a promising therapeutic option in SCI-related osteoporosis. INTRODUCTION:Osteoporosis development is a frequent complication related to SCI, especially at the sublesional level. Nevertheless, data on osteoporosis treatment after SCI is scarce, particularly short term after injury, when the highest bone loss is produced. The aim of this study was to analyze the efficacy of denosumab in the treatment of SCI-related osteoporosis. METHODS: Fourteen individuals aged 39 ± 15 years with osteoporosis secondary to recent SCI (mean injury duration 15 ± 4 months) were treated with denosumab for 12 months. Bone turnover markers (BTMs) (PINP, bone ALP, sCTx), 25-hydroxyvitamin D (25OHD) levels and bone mineral density (BMD) at the lumbar spine (LS), total hip (TH), and femoral neck (FN) were assessed at baseline and at 12 months. All participants received calcium and vitamin D supplementation. RESULTS: At 12 months, SCI denosumab-treated participants showed a significant increase in BMD at TH (+2.4 ± 3.6 %, p = 0.042), FN (+3 ± 3.6 %, p = 0.006), and LS (+7.8 ± 3.7 %, p < 0.001) compared to baseline values. Denosumab treatment was associated with significant decreases in BTMs (bone ALP -42 %, p < 0.001; PINP -58 %, p < 0.001, sCTx -57 %, p = 0.002) at 12 months. BMD evolution was not related to BTM changes or 25OHD serum levels. No skeletal fractures or serious adverse events were observed during follow-up. CONCLUSIONS: Treatment with denosumab increases lumbar and femoral BMD and decreases bone turnover markers in individuals with recent SCI. This drug may be a promising therapeutic option in SCI-related osteoporosis.
Entities:
Keywords:
Bone mineral density; Bone turnover markers; Denosumab; Osteoporosis; Spinal cord injury
Authors: Eric Orwoll; Christence S Teglbjærg; Bente L Langdahl; Roland Chapurlat; Edward Czerwinski; David L Kendler; Jean-Yves Reginster; Alan Kivitz; E Michael Lewiecki; Paul D Miller; Michael A Bolognese; Michael R McClung; Henry G Bone; Östen Ljunggren; Bo Abrahamsen; Ugis Gruntmanis; Yu-Ching Yang; Rachel B Wagman; Suresh Siddhanti; Andreas Grauer; Jesse W Hall; Steven Boonen Journal: J Clin Endocrinol Metab Date: 2012-06-21 Impact factor: 5.958
Authors: William A Bauman; Christopher M Cirnigliaro; Michael F La Fountaine; LeighAnn Martinez; Steven C Kirshblum; Ann M Spungen Journal: J Bone Miner Metab Date: 2014-08-27 Impact factor: 2.626
Authors: William P Waring; Fin Biering-Sorensen; Stephen Burns; William Donovan; Daniel Graves; Amitabh Jha; Linda Jones; Steven Kirshblum; Ralph Marino; M J Mulcahey; Ronald Reeves; William M Scelza; Mary Schmidt-Read; Adam Stein Journal: J Spinal Cord Med Date: 2010 Impact factor: 1.985
Authors: Laia Gifre; Joan Vidal; Josep L Carrasco; Xavier Filella; Silvia Ruiz-Gaspà; Africa Muxi; Enric Portell; Ana Monegal; Nuria Guañabens; Pilar Peris Journal: J Bone Miner Res Date: 2015-06 Impact factor: 6.741
Authors: C M Cirnigliaro; M J Myslinski; M F La Fountaine; S C Kirshblum; G F Forrest; W A Bauman Journal: Osteoporos Int Date: 2016-12-05 Impact factor: 4.507
Authors: L Abderhalden; F M Weaver; M Bethel; H Demirtas; S Burns; J Svircev; H Hoenig; K Lyles; S Miskevics; L D Carbone Journal: Osteoporos Int Date: 2016-12-06 Impact factor: 4.507
Authors: M E Holman; G Chang; M P Ghatas; P K Saha; X Zhang; M R Khan; A P Sima; R A Adler; A S Gorgey Journal: Osteoporos Int Date: 2021-01-14 Impact factor: 4.507
Authors: L Gifre; L Humbert; A Muxi; L Del Rio; J Vidal; E Portell; A Monegal; N Guañabens; P Peris Journal: Osteoporos Int Date: 2017-10-17 Impact factor: 4.507
Authors: L Gifre; S Ruiz-Gaspà; J L Carrasco; E Portell; J Vidal; A Muxi; A Monegal; N Guañabens; P Peris Journal: Osteoporos Int Date: 2017-06-04 Impact factor: 4.507
Authors: Nour Zleik; Frances Weaver; Robert L Harmon; Brian Le; Reshmitha Radhakrishnan; Wanda D Jirau-Rosaly; B Catharine Craven; Mattie Raiford; Jennifer N Hill; Bella Etingen; Marylou Guihan; Michael H Heggeness; Cara Ray; Laura Carbone Journal: J Spinal Cord Med Date: 2018-05-10 Impact factor: 1.985